U030 Managing Unique Conditions in Asian Skin
DESCRIPTION
Asians constitute over 60% of the world's population. The percentage of the United States population identifying as Asian is expected to double by the year 2050. Consequently, the demand for dermatologic care from this demographic will increase, requiring dermatologists to become more familiar with the diagnosis and treatment of Asian-specific skin diseases and cosmetic concerns. We will explore the characteristics of Asian skin and offer clinical pearls for diagnosing and managing prevalent skin concerns among Asian patients, including Riehl's melanosis, Hori's nevus, melasma, acral and nail melanoma, and scars.
LEARNING OBJECTIVES
Recognize unique characteristics of Asian skin.
Manage pigmentary disorders and scarring disorders in patients with Asian skin.
Summarize unique presentation of common skin disorders in Asian skin.
SCHEDULE
7:30 AM
Insights into Asian Skin: Characteristics and Clinical Pearls
Hye Jin Chung, MD, FAAD
7:40 AM
Diagnostic approach for early detection of acral and nail unit melanoma in Asians
Mi Ryung Roh, MD, PhD
7:55 AM
Practical approach to common facial pigmented lesions in Asians
Woraphong Manuskiatti, MD
8:15 AM
Approach To Scars In Asian Patients In 2024
Omar Ibrahimi, MD, PhD, FAAD
8:25 AM
Q&A
DIRECTOR
Hye Jin Chung, MD, FAAD
SPEAKERS
Omar Ibrahimi, MD, PhD, FAAD
Woraphong Manuskiatti, MD
Mi Ryung Roh, MD, PhD
HANDOUTS
DISCLOSURES
Hye Jin Chung, MD, FAAD
Galderma – Advisory Board(Fees); Recens Medical – Other(Grants/Research Funding); Regeneron Pharmaceuticals, Inc. – Investigator(Grants/Research Funding); Sonoma Pharmaceuticals – Advisory Board(Fees); The Skin of Color Society – Investigator(Grants/Research Funding);
Omar Ibrahimi, MD, PhD, FAAD
Accure, Inc – Advisory Board(No Compensation Received); Allergan, Inc – Advisory Board(Honoraria); AVAVA, LLC – Investigator(Grants/Research Funding); Cynosure-Lutronic – Consultant (1099 relationship)(Honoraria); Cytrellis Biosystems, Inc – Advisory Board(Honoraria); Quthero, Inc – Consultant (1099 relationship)(Honoraria); Unilever – Stockholder(Stock);
Woraphong Manuskiatti, MD
No financial relationships exist with ineligible companies.
Mi Ryung Roh, MD, PhD
No financial relationships exist with ineligible companies.